|
Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients. |
|
|
Consulting or Advisory Role - IMPAQ International |
Research Funding - Akcea Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - GE Healthcare |
Other Relationship - Journal of the American College of Radiology. (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; ION Pharma; Janssen; Oncopeptides; Roche |
Research Funding - Amgen; Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Metastat |
Consulting or Advisory Role - Adgero Biopharmaceuticals; AstraZeneca; Cardinal Health; Celgene; Celldex; Genentech/Roche; Juno Therapeutics; Lilly; Merrimack; Novartis; Pfizer; Prescient Therapeutics |
Research Funding - Deciphera (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Novartis (Inst); Prescient Therapeutics (Inst); Radius Health (Inst) |
Travel, Accommodations, Expenses - Adgero Biopharmaceuticals; AstraZeneca; Menarini Silicon Biosystems; Myriad Genetics; Pfizer; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbvie; Agios; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Genzyme; GlaxoSmithKline; Janssen-Ortho; Merck Sharp & Dohme; Novartis; Onyx; Pfizer; Sanofi; Sequenta; Syndax; Takeda |
|
|
Consulting or Advisory Role - Celgene |
Travel, Accommodations, Expenses - Celgene |